'Atac trial' diaporamas de présentation

Cost and Cancer Care

563 views • 47 slides

CONTROVERSIES IN ADJUVANT ENDOCRINE THERAPY AROMATASE INHIBITORS

CONTROVERSIES IN ADJUVANT ENDOCRINE THERAPY AROMATASE INHIBITORS. JAMES F BISHOP MD PROFESSOR OF CANCER MEDICINE, UNIVERSITY OF SYDNEY DIRECTOR, SYDNEY CANCER CENTRE ROYAL PRINCE ALFRED HOSPITAL, SYDNEY. 3 RD GENERATION AROMATASE INHIBITORS.

556 views • 36 slides

ACP: Breast Cancer Update

ACP: Breast Cancer Update. Elaine A. Muchmore, M.D. UC San Diego 10/20/07. Breast Cancer. Breast cancer affects more than 150,000 women each year, with a lifetime incidence of greater than 10%.

629 views • 19 slides

1 Leyland-Jones B et al. Proc SABCS 2010;Abstract S1-8.

Outcome According to CYP2D6 Genotype Among Postmenopausal Women with Endocrine-Responsive Early Invasive Breast Cancer Randomized in the BIG 1-98 Trial 1 Lack of Correlation between Gene Variants in Tamoxifen Metabolizing Enzymes with Primary Endpoints in the ATAC Trial 2.

302 views • 16 slides

A Distant recurrence - tamoxifen

A Distant recurrence - tamoxifen. *4/WT. 20%. WT/WT. 15%. * 4/* 4. Recurrence (%). 10%. 5%. 0%. 0. 2. 4. 6. 8. 10. Follow-up time [years]. No. of patients at risk. WT/WT. 402. 379. 353. 317. 249. 5. *4/WT. 149. 137. 131. 120. 95. 0. *4/*4. 37. 35.

243 views • 12 slides